JP2017526706A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526706A5
JP2017526706A5 JP2017513199A JP2017513199A JP2017526706A5 JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5 JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049213 external-priority patent/WO2016040498A1/en
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A JP2017526706A (ja) 2017-09-14
JP2017526706A5 true JP2017526706A5 (enExample) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (enExample)
EP (1) EP3193603A4 (enExample)
JP (1) JP2017526706A (enExample)
AU (1) AU2015315167A1 (enExample)
CA (1) CA2960274A1 (enExample)
WO (1) WO2016040498A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015315180A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamides as irreversible SMYD inhibitors
BR112017004612A2 (pt) 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
US10106510B2 (en) 2014-09-10 2018-10-23 Epizyme, Inc. Substituted isoxazoles for treating cancer
US10426168B2 (en) 2015-06-17 2019-10-01 Sumitomo Chemical Company, Limited Agent for controlling noxious arthropods
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (de) * 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療又は予防用nr2b受容体拮抗薬
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN101128454A (zh) * 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
CN101563082A (zh) 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
CA2684105C (en) * 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
KR101347303B1 (ko) * 2010-01-29 2014-01-06 한미사이언스 주식회사 단백질 키나아제 저해활성을 갖는 티에노[3,2-d]피리미딘 유도체
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
EP3868541A1 (en) * 2012-12-18 2021-08-25 Alcyone Lifesciences, Inc. Micro-molding device and system for making a catheter for reducing or preventing backflow in a delivery system
EP2968266B1 (en) * 2013-03-15 2019-05-01 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds in the treatment and/or prevention of cardiovascular diseases
WO2016040508A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
BR112017004612A2 (pt) 2014-09-10 2018-01-30 Epizyme, Inc. compostos, composição farmacêutica, usos de um composto, e kit
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
AU2015315180A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Isoxazole carboxamides as irreversible SMYD inhibitors
US10106510B2 (en) 2014-09-10 2018-10-23 Epizyme, Inc. Substituted isoxazoles for treating cancer
US20170253601A1 (en) * 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Similar Documents

Publication Publication Date Title
JP2017526706A5 (enExample)
JP2017528464A5 (enExample)
JP2016514695A5 (enExample)
JP2017527577A5 (enExample)
JP2017528460A5 (enExample)
JP2017538659A5 (enExample)
JP2019514950A5 (enExample)
MA40581A (fr) Dérivés pyridone utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2017527576A5 (enExample)
RU2014112345A (ru) Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение
CN103402519B (zh) 肿瘤治疗剂
JP2020515571A5 (enExample)
JP2017510641A5 (enExample)
CA3094449A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
JP2013064024A5 (enExample)
IL272697B2 (en) A polymorphic form of TG02
JP2022541633A (ja) がんの治療のためのezh2阻害併用療法
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JP2017528461A5 (enExample)
HRP20211877T1 (hr) Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
JP2020506884A5 (enExample)
JP2013528215A5 (enExample)
TN2010000139A1 (en) Organic compounds
JP2013505939A (ja) 組合せ